期刊
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
卷 108, 期 7, 页码 -出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/jnci/djv439
关键词
-
类别
资金
- Science and Technology Planning Project of Beijing City [Z151100003915076]
- National Natural Science Foundation of China [31270820, 81230061]
The genetic modification and characterization of T-cells with chimeric antigen receptors (CARs) allow functionally distinct T-cell subsets to recognize specific tumor cells. The incorporation of costimulatory molecules or cytokines can enable engineered T-cells to eliminate tumor cells. CARs are generated by fusing the antigen-binding region of a monoclonal antibody (mAb) or other ligand to membrane-spanning and intracellular-signaling domains. They have recently shown clinical benefit in patients treated with CD19-directed autologous T-cells. Recent successes suggest that the modification of T-cells with CARs could be a powerful approach for developing safe and effective cancer therapeutics. Here, we briefly review early studies, consider strategies to improve the therapeutic potential and safety, and discuss the challenges and future prospects for CAR T-cells in cancer therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据